FDA Proposes Ban on Compounded Obesity and Diabetes Drugs, Names New Acting Director
The FDA proposed excluding semaglutide and tirzepatide from compounding lists, citing no clinical need. Katherine Szarama was named acting director of...
Xeber.world
Ozempic
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
FDA Proposes Ban on Compounded Weight-Loss Drugs, Targeting Semaglutide and Tirzepatide
The FDA has proposed excluding semaglutide and tirzepatide, key ingredients in popular weight-loss and diabetes drugs like Wegovy, Ozempic, Mounjaro,...
Study Reveals Mounjaro Causes More Lean Body Mass Loss Than Ozempic—Here’s Why It Matters
A new study suggests tirzepatide medications like Mounjaro may lead to greater lean body mass loss compared to semaglutide drugs like Ozempic. Researc...
New Study Finds GLP-1 Drugs May Increase Cognitive Impairment Risk—But There’s a Key Explanation
A new retrospective study presented at the American Academy of Neurology annual meeting suggests GLP-1 drugs like Ozempic may increase cognitive impai...
How Ambien, Ozempic, and Other Blockbuster Drugs Shape Society: A Podcast Deep Dive
The 'First Opinion Podcast' explores the surprising societal impacts of widely used drugs like Ambien, Ozempic, and EpiPens. Host Torie Bosch intervie...
The Risks and Reality of Bootleg Peptides in the Wellness Boom
Peptides are gaining popularity for weight loss, skin health, and anti-aging, but their legality and safety are often unclear. With growing demand and...
Stopping GLP-1 Drugs Like Ozempic or Wegovy May Reverse Heart Benefits, Study Warns
A new study reveals that discontinuing GLP-1 medications such as Ozempic or Wegovy can reverse their cardiovascular benefits within six months. Resear...
GLP-1 Drugs Such as Ozempic and Wegovy May Reduce Depression and Anxiety Risks, Study Finds
A large Swedish study published in The Lancet Psychiatry suggests GLP-1 receptor agonists like Ozempic and Wegovy may lower the risk of worsening depr...
Genetics May Determine How Well GLP-1 Weight Loss Drugs Like Ozempic Work
New research reveals that around 10% of people may have genetic variations causing 'GLP-1 resistance,' reducing the effectiveness of popular weight lo...